Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015 (2015), Article ID 628340, 10 pages
http://dx.doi.org/10.1155/2015/628340
Research Article

CCR9 Antagonists in the Treatment of Ulcerative Colitis

ChemoCentryx, Inc., 850 Maude Avenue, Mountain View, CA 94043, USA

Received 7 November 2014; Revised 18 June 2015; Accepted 25 June 2015

Academic Editor: Jens Geginat

Copyright © 2015 Pirow Bekker et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

CCX025 is a potent inhibitor of T-cell migration. Increasing concentrations of CCX025 inhibit the chemotaxis of Molt-4 T-cells which constitutively express human CCR9, to human CCL25 in an in vitro migration assay. CCX025 was potent when the assay was run in buffer (a) or in 100% human serum (b). CCX025 inhibits the in vitro chemotaxis of primary mouse thymocytes to murine CCL25 (c). In an in vivo T-cell trafficking model in mice, CCX025 inhibited the recruitment of CD8+ T-cells to the small intestine of OT-1 mice given an oral challenge of ovalbumin (d)

  1. Supplementary Material